This study checks how well a drug called vixarelimab works for lung diseases, specifically Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD). IPF is a disease where lung tissue gets scarred for unknown reasons, making it hard to breathe. SSc-ILD is lung scarring that happens with a disease where the skin and other organs become thick and hard. The study compares vixarelimab to a placebo, which is a fake treatment that looks like the real drug but doesn't have any active ingredients. Participants take part for 52 weeks, and if they complete this, they can join an additional 52-week phase with the actual drug.

• The study lasts up to 104 weeks (2 years) if you join the optional phase.
• You may continue your current treatments if stable and according to the study rules.
• Participants should not have had a lung transplant or certain infections recently.

Deciding to participate in a study should be discussed with your doctor to ensure it's the right choice for your health condition.